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THE COST-EFFECTIVENESS OF PROSTATE-SPECIFIC
ANTIGEN SCREENING FOR PROSTATE CANCER DETECTION
Tencer T, Hay JW
University of Southern California, Los Angeles, CA, USA
OBJECTIVE: To compare the cost-effectiveness of PSA screen-
ing for the detection of prostate cancer in the United States versus
no screening. Incremental Cost per Quality-Adjusted Life Year
(QALY) using a lifetime decision model was used. METHODS:
Estimates of cost, utility and probabilities were taken from lit-
erature, clinical experts and the Bureau of Labor Statistics.
Cancer speciﬁc mortality rates were determined by the grade of
the disease. The DEALE method was used to calculate average
life expectancy of men in the general population, using the life
tables from the CDC. A cohort of men stratiﬁed into six age
groups: 45–59, 50–54, 55–59, 60–64, 65–69, and 70–74. The
time horizon was a lifetime; future values discounted at 3% and
the perspective was societal. RESULTS: In 2002 USD, a one time
screening of each age group was found to be cost-effective. The
incremental cost-effectiveness ratio (ICER) ranged from $5291
per life year saved for men aged 45–49 to $12,219 per life 
year saved for men aged 70–74. After adjusting for quality of
life, we found that the ICER ranged from $6,452/QALY to
$14,902/QALY for men aged 70–74. Results of sensitivity analy-
sis show lowering the positive predicted value of the PSA test by
approximately 30% increased cost/QALY from 8–12%, increas-
ing it by about 20% decreases the ratio about 3–5%. The model
remained cost-effective after varying the cost of Radical Prosta-
tectomy, the mortality from surgery and the percentage of local
prostate cancers found by screening. CONCLUSION: This
model found a one time PSA screening for prostate cancer in each
age group to be cost-effective relative to no screening.
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THE COST-EFFECTIVENESS OF HERCEPTIN® IN ADJUVANT
SETTING: THE HERA TRIAL
Neyt M1, Cocquyt V2,Albrecht J1
1Ghent University, Gent, Belgium; 2University Hospital Gent, Gent,
Belgium
OBJECTIVES: Trastuzumab as adjuvant therapy is being tested
in a number of large randomised trials. Our purpose is to cal-
culate the cost implications of using trastuzumab as in the HerA
trial and provide information on the product’s value for money.
METHODS: Standard breast-cancer treatment models were set
up for different subpopulations according to stage (I, II, III) and
menopausal condition (·,Ò 50 years). They were constructed from
the hospital’s point of view to analyse the impact of new treat-
ments on real costs. Costs were calculated using the micro-
costing method and gathered in close collaboration with the staff
of our treatment centre. The comparator or benchmark in our
analysis was the existing practice. On the basis of the HerA trial
and experts opinions, trastuzumab monotherapy was imple-
mented in our treatment model. In addition to a sensitivity analy-
sis, a threshold analysis was performed to target the current
cost-effectiveness level while medical effectiveness and the price
of trastuzumab were used as variable parameters. RESULTS:
Trastuzumab treatment as in the HerA trial was very expensive
(37,980 €/patient). The product as such is expensive and treat-
ment is maintained for one year. The impact on total costs
depends on the percentage of patients being eligible for
trastuzumab treatment. Monthly treatment costs were largely
inﬂuenced by the discount ratio, the price of medication and the
ﬂow through of patients to metastatic treatment. According to
our threshold analysis, price discounts are indispensable to get
value for money unless great effectiveness improvements can be
realised. CONCLUSIONS: With a model reﬂecting real-world
conditions, cost implications of using trastuzumab in adjuvant
setting can be calculated before the product is widely spread.
When the ongoing trials cast light on new elements, new analy-
sis must be performed. The model provides essential information
for price-setting policies as well as for policymakers considering
reimbursement.
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ECONOMIC IMPACT OF PROSTATE-SPECIFIC ANTIGEN
DOUBLING TIME IN PATIENTS WITH HORMONE-
REFRACTORY PROSTATE CANCER
Mulani P1, Botteman M2, Hay JW3, Cifaldi M1
1Abbott Laboratories, Abbott Park, IL, USA; 2PharMerit North
America, Bethesda, MD, USA; 3University of Southern California,
Los Angeles, CA, USA
OBJECTIVE: There is limited information about cost implica-
tions of prostate-speciﬁc antigen doubling time (PSADT) in
patients with hormone-refractory prostate cancer (HRPCA).
This research was undertaken to assess the association between
PSADT <four-months with health care costs in HRPCA patients.
METHODS: A health care claims database (Pharmetrics®) 
with data from 70 managed care plans (1995–2002) was used.
HRPCA patients were identiﬁed using a pre-speciﬁed algorithm.
For each patient, we determined whether his PSADT was < or >
four-months. Costs were broken down by service type; manage-
ment, surgery, ancillary, facility and pharmacy. The costs of
HRPCA patients with PSADT < four-months were compared to
the cost of patients with PSADT > four-months. In addition, a
within-group analysis compared the cost of patients with PSADT
< four-months before and after reaching a PSADT < four-months
(the “event”). RESULTS: In total, 413 HRPCA patients were
identiﬁed, of which 71 HRPCA had PSADT < four-months. The
per-month health care cost (post-event) for patients who experi-
enced the event were, total $1524 (S.D.187.3), ancillary ($415
[56.1)), management ($471[69.4)), facility ($209 [47.5)), phar-
macy ($346 [33.3)), and surgery ($84 [27.9]), whereas the cor-
responding pre-event costs were, total ($1000 [141.1]) ancillary
($297 [89.2)), management ($205 [41.7]), facility ($25 [15.9]),
pharmacy ($436 [51.3]), and surgery ($37 [14.5)). The monthly
costs for patients who did not experience the event were total
$1064 [52.1], ancillary ($315 [20.6]), management ($319
[21.4)), facility ($115 [12.3)), pharmacy ($251 [10.2]), and
surgery ($64 [5.5]). Most of the between- and within-group com-
parisons were signiﬁcant (P < 0.05). CONCLUSION: HRPCA
patients with PSADT <four-months had signiﬁcantly higher
health care costs (post event). Therapies that extend PSADT have
a potential to show signiﬁcant cost savings.
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THE COST OF CANCER IN KOREA: 1999–2003
Jung YH, Ko S
Korea Institute for Health and Social Affairs, Seoul, South Korea
OBJECTIVE: Cancer has been the ﬁrst leading cause of death in
Korea. During the period of 1993~2003, the mortality rate of
cancer increased the most among the 10 major causes of death.
The aim of the study is to estimate the cost of cancer in Korea
during 1999~2003. METHODS: We estimate both direct and
indirect cost of cancer using a prevalence-based approach. Direct
cost estimates include medical expenditures, trafﬁc cost and care-
givers’ cost. Indirect costs representing the loss of productivity
are estimated based on human capital theory. The cost estimates
reported here are calculated at 0% discount rate. The major data
sources are National Health Insurance Statistical Yearbook,
Annual Report on the Cause of Death Statistics, and Survey
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Report on Wage Structure. We also use other information such
as the Korean Statistical Information System. RESULTS: The
estimated costs of cancer are as follows: 9.60 billion US PPP$ ($
hereafter) in 1999, $9.60 billion in 2000, $9.62 billion in 2001,
$9.01 billion in 2002, and $9.87 billion in 2003. We ﬁnd that
indirect cost accounts for about 80% of total cost during that
period, but the proportion has been dropped since 2000; from
84.6% in 2000 to 78.7% in 2003. The proportions of the 
cost of male and female cancer patients are about 77% and 23%
respectively during the period. The cost of three major cancers
in 2003 accounts for 53.3% of total cost of cancers: the cost of
liver cancer is $2.26 billion (22.9% of total cost of all cancers);
$1.67 billion (16.9%) in stomach cancer; and $1.33 billion
(13.5%) in bronchial and lung cancer. CONCLUSIONS: The
cost of cancer has been steadily increasing from 1999~2003
except 2002, while the proportion of indirect costs has gradu-
ally decreased since 2000.
PCN12
ESTIMATING COSTS OF UNCONTROLLED CHEMOTHERAPY-
INDUCED NAUSEA AND VOMITING AMONG WORKING-AGE
CANCER PATIENTS
Shih YCT1, Han S2, Zhao L1, Elting LS1
1University of Texas MD Anderson Cancer Center, Houston,TX, USA;
2Rice University, Houston,TX, USA
OBJECTIVES: Poorly controlled CINV may lead to additional
ofﬁce or emergency room visits, thus, increasing the overall costs
of cancer care. This study estimates the societal costs of uncon-
trolled CINV for working-age cancer patients. METHODS:
Employees or spouse and/or dependents with cancer who
received highly or moderately emetogenic chemotherapy were
identiﬁed from a 1997–2002 proprietary dataset linking medical
claims to work-loss information. Patients were followed from the
earliest date of chemotherapy for up to six-months, excluding
those with less than three-months of continuous enrollment.
Direct medical costs were measured using payments, normalized
as monthly, and updated to 2004 USD. Work loss days were
identiﬁed from employment records. Costs of uncontrolled
CINV were derived by comparing medical costs and work-loss
days for three groups, patients with uncontrolled CINV and 
no ER visit, with uncontrolled CINV and ER visit, and with 
controlled CINV, using the Wilcoxon Mann-Whitney test in 
univariate analyses. All patients with uncontrolled CINV were
pooled as one group in multivariate analysis. RESULTS: In all,
2,071 patients were identiﬁed; 25% required medical care for
uncontrolled CINV; 2% had ER visits. Compared with patients
with controlled CINV ($8132), total direct costs were signiﬁ-
cantly higher for patients with uncontrolled CINV, no ER
($10,376, P < 0.001) and uncontrolled CINV and ER ($12,810,
P < 0.001), respectively. Estimated work-loss days were 6.1, 7.2,
and 8.9 days the above groups, respectively. After controlling 
for demographics, geographic regions, and comorbidities, the
difference in monthly medical costs between the controlled 
and uncontrolled group was $2619 (P < 0.001). However, the
difference in work-loss (0.21 days) was no longer signiﬁcant 
(P = 0.73). CONCLUSIONS: Uncontrolled CINV was associated
with a signiﬁcant increase in medical costs. For patients with
uncontrolled CINV but no ER visit, increases in cost were driven
by outpatient care, whereas for those with ER visits, inpatient
care was the major cost driver.
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SURVIVAL AND COST FOLLOWING BREAST CANCER
RECURRENCE: ESTIMATES FROM SEER-MEDICARE DATA
Thompson D1, O’Sullivan AK1, Stokes M1, Montoya E1, Earle C2,
Winer EP2, Kulig K3,Weinstein MC4
1Innovus Research, Inc, Medford, MA, USA; 2Dana-Farber Cancer
Institute, Boston, MA, USA; 3Pﬁzer Inc, New York, NY, USA; 4Harvard
School of Public Health & Innovus Research, Inc, Boston, MA, USA
OBJECTIVES: A variety of pharmacologic therapies are avail-
able or in development for the prevention of breast cancer recur-
rence. Assessing the beneﬁts of these treatments is compromised
by a paucity of data on the impact of recurrence on economic
costs and patient survival. The purpose of this study was to shed
light on these issues. METHODS: We conducted a retrospective
analysis of SEER-Medicare data, which consists of information
from the SEER cancer registry linked to administrative claims
from the Medicare program. All patients in SEER who were
diagnosed with and treated for primary breast cancer during
1991–1993 were identiﬁed, and their subsequent Medicare
claims histories were scanned for evidence of recurrence. Patients
were stratiﬁed according to type of recurrence (local, contralat-
eral, or distant) and their Medicare claims further scanned from
the time of their recurrence through 2002 to assess patterns of
survival and health care costs (which were inﬂated to 2003
dollars). Patients who did not have recurrence were used as con-
trols. Techniques pioneered by Lin for the analysis of censored
cost data were used to estimate ten-year undiscounted costs of
recurrence by type. RESULTS: We identiﬁed 8725 patients in
SEER who were diagnosed with and treated for primary breast
cancer during 1991–1993, including 1485 who subsequently 
had a recurrence (local, 759; contralateral, 228; distant, 498).
Median survival was 124.0 months among controls, versus 
42.8 and 7.1 months among patients with local and distant
recurrence, respectively; 52.4% of patients with contralateral
recurrence remained alive after all data were censored at 93.5
months. Cumulative ten-year costs following local, contralateral,
and distant breast cancer recurrence exceeded those of controls
by $84,406, $29,609, and $222,106, respectively. CONCLU-
SION: The impact of breast cancer recurrence on patient sur-
vival and economic costs is substantial and varies considerably
by type.
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IS COMBINED ANDROGEN BLOCKADE WITH BICALUTAMIDE
COST-EFFECTIVE COMPARED WITH COMBINED ANDROGEN
BLOCKADE WITH FLUTAMIDE?
Ramsey S1,Veenstra DL2, Clarke L3, Penson D4, Gandhi S5,
Hirsch M5
1Fred Hutchinson Cancer Research Center, Seattle, WA, USA;
2University of Washington, Seattle, WA, USA; 3Cornerstone
Northwest, Lynden, WA, USA; 4University of Southern California,
Los Angeles, CA, USA; 5AstraZeneca, Wilmington, DE, USA
OBJECTIVES: Both bicalutamide and ﬂutamide are commonly
used in combined androgen blockade (CAB) for prostate cancer.
Although bicalutamide is more costly than ﬂutamide, it is impor-
tant that efﬁcacy and quality of life outcomes as well as com-
pliance, and side effects are also taken into consideration when
determining whether CAB with bicalutamide is a cost-effective
option as compared to CAB with ﬂutamide. Unfortunately, there
have been no well-designed cost-effectiveness analyses compar-
ing bicalutamide vs. ﬂutamide as part of CAB. The goal of this
study was to determine the cost-effectiveness of CAB with bica-
lutamide vs. CAB with ﬂutamide in men with stage D2 prostate
cancer. METHODS: A decision model was created to compare
treatment strategies. Survival and side effect information was
